Genmab A/S (GNMSF)
509.50
0.00 (0.00%)
USD |
OTCM |
Nov 13, 16:00
Genmab Enterprise Value : 34.67B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 34.67B |
| November 12, 2026 | 34.67B |
| November 11, 2026 | 36.61B |
| November 10, 2026 | 36.61B |
| November 09, 2026 | 36.91B |
| November 06, 2026 | 35.68B |
| November 05, 2026 | 36.42B |
| November 04, 2026 | 36.91B |
| November 03, 2026 | 38.01B |
| November 02, 2026 | 38.01B |
| October 30, 2026 | 38.01B |
| October 29, 2026 | 37.49B |
| October 28, 2026 | 39.00B |
| October 27, 2026 | 30.34B |
| October 26, 2026 | 30.86B |
| October 23, 2026 | 30.86B |
| October 22, 2026 | 27.23B |
| October 21, 2026 | 27.23B |
| October 20, 2026 | 27.23B |
| October 19, 2026 | 26.58B |
| October 16, 2026 | 25.91B |
| October 15, 2026 | 25.91B |
| October 14, 2026 | 25.91B |
| October 13, 2026 | 25.91B |
| October 12, 2026 | 25.91B |
| Date | Value |
|---|---|
| October 09, 2026 | 25.91B |
| October 08, 2026 | 26.58B |
| October 07, 2026 | 26.58B |
| October 06, 2026 | 26.46B |
| October 05, 2026 | 27.75B |
| October 02, 2026 | 25.17B |
| October 01, 2026 | 25.17B |
| September 30, 2026 | 25.17B |
| September 29, 2026 | 24.96B |
| September 28, 2026 | 24.96B |
| September 25, 2026 | 24.84B |
| September 24, 2026 | 24.47B |
| September 23, 2026 | 23.99B |
| September 22, 2026 | 24.67B |
| September 21, 2026 | 24.25B |
| September 18, 2026 | 24.25B |
| September 17, 2026 | 24.25B |
| September 16, 2026 | 24.13B |
| September 15, 2026 | 24.01B |
| September 14, 2026 | 23.43B |
| September 11, 2026 | 23.43B |
| September 10, 2026 | 23.43B |
| September 09, 2026 | 23.43B |
| September 08, 2026 | 23.43B |
| September 04, 2026 | 23.43B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ascendis Pharma A/S | 17.48B |
| Zealand Pharma A/S | 407.51M |
| Bavarian Nordic A/S | 2.199B |
| Evaxion AS | 15.96M |
| ACADIA Pharmaceuticals, Inc. | 2.335B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 342.00M |
| Revenue (Quarterly) | 1.187B |
| Total Expenses (Quarterly) | 845.00M |
| EPS Diluted (Quarterly) | 5.480 |
| Gross Profit Margin (Quarterly) | 90.31% |
| Profit Margin (Quarterly) | 28.81% |
| Earnings Yield | 2.29% |
| Operating Earnings Yield | 4.05% |
| Normalized Earnings Yield | 2.861 |